Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Patricia JohanssonLudger Klein-HitpassAlexander RöthMichael MöllmannHans Christian ReinhardtUlrich DührsenJan DürigPublished in: European journal of haematology (2020)
These data indicate that PIGA mutations were acquired during or after completion of alemtuzumab treatment.